PubMed · 14784624
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
R WRIGHT. 1950. Fibrosarcoma.. https://pubmed.ncbi.nlm.nih.gov/14784624/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Myxofibrosarcoma is common in the extremities, but rare in the head and neck region. Hypopharyngeal myxofibrosarcoma has not been reported previously. We report the first case of a patient with myxofibrosarcoma of the hypopharynx. We examined this patient once a month after the operation, and there has been no local recurrence and no distant metastasis. Sarcomas are rare in the hypopharynx, but we have to bear in mind their possibility. Though a low-grade myxofibrosarcoma is a low-grade malignancy, complete resection should be done. We have to pay more attention planning the treatment for neoplastic diseases.
CASE REPORT: A primary giant infantile fibrosarcoma of the scalp in a 6-month-old boy is reported. He presented with a rapidly enlarging right paramedian parietal scalp swelling since birth. There were no signs of raised intracranial tension. Magnetic resonance (MR) imaging of the brain revealed a large vascular scalp tumor extending over the posterior frontal and parietal region bilaterally crossing the midline. There was no intracranial extension. Carotid angiography revealed an extremely vascular tumor supplied by the external carotid artery branches. The tumor was completely resected through a curvilinear scalp incision. Histology was consistent with diagnosis of an infantile fibrosarcoma. The patient had an uneventful course and received no postoperative adjuvant therapy. MR imaging of the brain at follow-up after 5 years showed no evidence of recurrence of tumor. At follow-up after 10 years, he is asymptomatic and leading an active life. DISCUSSION: The pathology and management of primary scalp fibrosarcoma is discussed, and the relevant literature is briefly reviewed.
PURPOSE: PCK3145 is a synthetic peptide corresponding to amino acids 31-45 of prostate secretory protein 94, which can reduce experimental skeletal metastases and prostate tumor growth in vivo. Part of its biological action involves the reduction of circulating plasma matrix metalloproteinase (MMP)-9, a crucial mediator in extracellular matrix (ECM) degradation during tumor metastasis and cancer cell invasion. The antimetastatic mechanism of action of PCK3145 is however, not understood. EXPERIMENTAL DESIGN: HT-1080 fibrosarcoma cells were treated with PCK3145, and cell lysates used for immunoblot analysis of small GTPase RhoA and membrane type (MT)1-MMP protein expression. Conditioned media was used to monitor soluble MMP-9 gelatinolytic activity by zymography and protein expression by immunoblotting. RT-PCR was used to assess RhoA, MT1-MMP, MMP-9, RECK, and CD44 gene expression. Flow cytometry was used to monitor cell surface expression of CD44 and of membrane-bound MMP-9. Cell adhesion was performed on different purified ECM proteins, while cell migration was specifically performed on hyaluronic acid (HA). RESULTS: We found that PCK3145 inhibited HT-1080 cell adhesion onto HA, laminin-1, and type-I collagen suggesting the common implication of the cell surface receptor CD44. In fact, PCK3145 triggered the shedding of CD44 from the cell surface into the conditioned media. PCK3145 also inhibited MMP-9 secretion and binding to the cell surface. This effect was correlated to increased RhoA and MT1-MMP gene and protein expression. CONCLUSIONS: Our data suggest that PCK3145 may antagonize tumor cell metastatic processes by inhibiting both MMP-9 secretion and its potential binding to its cell surface docking receptor CD44. Such mechanism may involve RhoA signaling and increase in MT1-MMP-mediated CD44 shedding. Together with its beneficial effects in clinical trials, this is the first demonstration of PCK3145 acting as a MMP secretion inhibitor.